An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option
An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option
This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated time on study treatment is 3-12 months.
Inclusion Criteria:
Exclusion Criteria:
Sabadell, Barcelona, Barcelona 08208, Spain
Sant Coloma Gramenet, Barcelona 08923, Spain
Torrevieja, Cantabria 03180, Spain
Navarra, Navarre 31008, Spain